A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
The RENOIR study is testing a new drug called Rosnilimab for adults aged 18 to 65 who have moderate to severe rheumatoid arthritis. This condition causes pain and swelling in joints. We are comparing Rosnilimab to a 'placebo' (a dummy drug with no active ingredients) to see if it's both safe and effective in improving symptoms. Participants will be randomly assigned to receive either Rosnilimab or the placebo. Researchers will carefully monitor participants throughout the study to understand how the new medication works and if it can offer a new treatment option for rheumatoid arthritis. Taking part could help us learn more about this condition and discover new ways to manage it, potentially benefiting many people in the future.
Överblick
Vad handlar denna studie om?
This study, called RENOIR, is looking into a new medicine named Rosnilimab for people living with rheumatoid arthritis. Rheumatoid arthritis is a long-term condition that causes pain, swelling, and stiffness in the joints. For some people, current treatments don't work well enough, and new options are needed.
The main goal of this study is to find out if Rosnilimab is safe to use and whether it can help improve the symptoms of moderate to severe rheumatoid arthritis. To do this, some people in the study will receive Rosnilimab, while others will receive a 'placebo', which looks like the study drug but doesn't contain any active medicine. This comparison helps us understand the true effects of Rosnilimab.
By taking part, you could contribute to important research that might lead to a new treatment for rheumatoid arthritis. This could potentially help improve the lives of many people with this condition in the future.
Viktiga punkter
- Tests a new medicine (Rosnilimab) for rheumatoid arthritis.
- Compares Rosnilimab to a dummy treatment (placebo).
- Aimed at adults aged 18-65 with moderate to severe RA.
- Could help find new treatment options for rheumatoid arthritis.
- Deltagande är frivilligt och du kan lämna när som helst.
Vem kan vara berättigad?
To join this study, you generally need to be an adult aged 18 to 65 years old and have been diagnosed with rheumatoid arthritis for at least three months. It's important that you are currently taking one or two standard rheumatoid arthritis medications (DMARDs) and have been on a steady dose of these for at least eight weeks before the study begins. You should also have found that at least one of your previous rheumatoid arthritis medications hasn't worked well enough for you, or you haven't been able to tolerate it.
There are also some reasons why you might not be able to join. For example, if you have other inflammatory joint diseases, or if you've had certain types of cancer in the last five years, you wouldn't be eligible. The study also can't include people who have a weakened immune system, or if you are pregnant or breastfeeding. If you've previously taken certain immune-system-affecting drugs, this would also prevent you from joining.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du mellan 18 och 65 år gammal?
- Do you have a diagnosis of rheumatoid arthritis for at least 3 months?
- Are you currently taking 1 or 2 standard rheumatoid arthritis medicines (DMARDs) at a steady dose?
- Has at least one of your past rheumatoid arthritis medicines not worked well or caused problems?
- Är du inte gravid eller ammar?
Vad innebär deltagande?
If you decide to take part, you'll be randomly assigned to either receive Rosnilimab or a placebo (a dummy drug). This means neither you nor your study doctor will know which treatment you are receiving. You will need to attend regular appointments at the clinic over a period of time. These visits will involve various health checks, blood tests, and discussions about how you are feeling and any symptoms you are experiencing. You will also be given the study medication to take as instructed. The total duration of your participation in the study, including all follow-up, will be explained in detail by the study team.
Potentiella risker och fördelar
Platser (92)
- AnaptysBio Investigative Site 10-132Verifierat postnummerFlagstaff, United States
- AnaptysBio Investigative Site 10-130Verifierat postnummerGlendale, USA
- AnaptysBio Investigative Site 10-129Verifierat postnummerPhoenix, USA
- AnaptysBio Investigative Site 10-131Verifierat postnummerTucson, USA
- AnaptysBio Investigative Site 10-105Verifierat postnummerCovina, USA
- Anaptys Bio Investigative Site 10-119Verifierat postnummerRancho Mirage, USA
- AnaptysBio Investigative Site 10-113Verifierat postnummerSan Diego, USA
- AnaptysBio Investigative Site 10-127Verifierat postnummerSan Francisco, USA
- AnaptysBio Investigative Site 10-136Verifierat postnummerTemecula, United States
- AnaptysBio Investigative Site 10-133Verifierat postnummerUpland, USA
- AnaptysBio Investigative Site 10-112Endast stadWhitter, United States
- AnaptysBio Investigative Site 10-103Verifierat postnummerAventura, USA
Vanliga frågor
What is rheumatoid arthritis?
Rheumatoid arthritis is a long-term condition that causes your immune system to mistakenly attack your joints, leading to pain, swelling, and stiffness.
Vad är en 'placebo'?
A placebo is a dummy treatment that looks just like the study drug but contains no active medicine. It helps researchers fairly compare the new drug's effects.
Kommer jag att veta om jag får läkemedlet eller placebon?
No, you won't. This is called 'double-blind,' and it means neither you nor the doctors will know, to keep the study results fair.
Hur länge varar studien?
The precise length will be explained by the study team, but it involves several months of treatment and follow-up visits.
Kan jag sluta delta om jag ändrar mig?
Yes, you can stop participating at any point, for any reason, without it affecting your current medical care.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.